First human tests begin for new lung disease pill

NCT ID NCT07225296

Summary

This is an early-stage study to check the safety of a new oral drug called GNS-3545, which is being developed for a serious lung scarring disease called idiopathic pulmonary fibrosis (IPF). The study involves 72 healthy adult volunteers who will receive either the drug or a placebo to see how their bodies react to it. The main goal is to understand the drug's safety, how it moves through the body, and if food affects its absorption.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Pharmaron CPC, Inc.

    RECRUITING

    Baltimore, Maryland, 21201, United States

Conditions

Explore the condition pages connected to this study.